PhIII dealmaking frenzy in i/o continues as AstraZeneca follows PACIFIC with a new Incyte IDO1 combo
Incyte CEO Hervé Hoppenot made it clear a long time ago that he was happily fast and loose about which approved PD-(L)1 drug he partnered with on his IDO1 drug epacadostat. He launched pivotal combo studies with Merck and Bristol-Myers Squibb, and now he’s kicking off a new Phase III tie-up with AstraZeneca’s Imfinzi (durvalumab) in stage III non-small cell lung cancer, continuing a relationship that dates back three years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.